Clinical Trial Update: The Efficacy and Safety of Hetrombopag in Primary Prevention of Thrombocytopenia Induced by the Niraparib Maintenance in Advanced Ovarian Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial assessing hetrombopag for primary prevention of niraparib-induced thrombocytopenia in advanced ovarian cancer patients; efficacy and safety data n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Thrombocytopenia

Drugs mentioned

• Hetrombopag (hetrombopag)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Thrombocytopenia | Phase 2 | Status: UNKNOWN